SIADH / Hyponatremia
Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.
Where it strikes
Fine-tuning of Na, K, Mg, acid & water
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ overall reversibility
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately siadh / hyponatremia is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. 3 of 4 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
- RetifanlimabPD-1 immune checkpoint inhibitor · FAERS only14.21 (7.28–27.74) · n=9 Reporting signal, fragile (few reports).
- ImlunestrantOral selective estrogen-receptor degrader (SERD) · FAERS only13.20 (4.85–35.96) · n=4 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- Denileukin diftitoxImmunotoxin (IL-2–diphtheria) · FAERS only10.01 (2.45–41.00) · n=2 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- Nimustine (ACNU)Nitrosourea (alkylating) · FAERS only10.01 (2.45–41.00) · n=2 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- RelacorilantSelective glucocorticoid-receptor antagonist · FAERS only9.94 (3.66–27.04) · n=4 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- InfigratinibFGFR inhibitor · FAERS only8.80 (2.15–35.93) · n=2 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- SelinexorXPO1 (nuclear export) inhibitor7.82 (6.94–8.81) · n=280 * Reporting signal, on terms consistent with the lesion rather than naming it.
- LifileucelTumor-infiltrating lymphocyte (TIL) therapy · FAERS only6.82 (3.38–13.77) · n=8 Reporting signal, fragile (few reports).
- MitotaneAdrenolytic · FAERS only6.36 (4.78–8.48) · n=48 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Interleukin-2 (high-dose)Cytokine6.34 (4.48–8.96) · n=33 Reporting signal.
- PentostatinPurine analog (ADA inhibitor)5.87 (3.23–10.67) · n=11 Reporting signal.
- NaxitamabAnti-GD2 antibody · FAERS only5.81 (2.58–13.05) · n=6 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- CisplatinPlatinum agent5.47 (5.22–5.74) · n=1,756 Reporting signal.
- FutibatinibFGFR inhibitor · FAERS only5.44 (2.24–13.20) · n=5 Reporting signal, fragile (few reports).
- VinblastineVinca alkaloid4.67 (3.38–6.43) · n=38 Reporting signal.
- AtezolizumabAnti-PD-L1 antibody3.88 (3.56–4.24) · n=525 Reporting signal.
- SelpercatinibRET inhibitor3.37 (2.06–5.51) · n=16 Reporting signal.
- CarboplatinPlatinum agent3.26 (3.11–3.42) · n=1,742 Reporting signal.
- VincristineVinca alkaloid3.14 (2.84–3.47) · n=386 Reporting signal.
- PemetrexedAntifolate2.75 (2.50–3.02) · n=448 Reporting signal.
- NivolumabPD-1 checkpoint inhibitor2.74 (2.58–2.90) · n=1,118 Reporting signal.
- DabrafenibBRAF inhibitor2.26 (1.96–2.59) · n=200 * Reporting signal, on terms consistent with the lesion rather than naming it.
- TemozolomideAlkylator2.23 (1.94–2.56) · n=199 * Reporting signal, on terms consistent with the lesion rather than naming it.
- CyclophosphamideOxazaphosphorine alkylator2.13 (2.03–2.24) · n=1,586 Reporting signal.
- VismodegibHedgehog (SMO) inhibitor2.08 (1.67–2.60) · n=78 * Reporting signal, on terms consistent with the lesion rather than naming it.
- TamoxifenSERM2.02 (1.52–2.67) · n=49 * Reporting signal, on terms consistent with the lesion rather than naming it.
- CytarabineNucleoside analog1.92 (1.75–2.09) · n=506 Reporting signal.
- VinorelbineVinca alkaloid1.78 (1.35–2.33) · n=52 * Reporting signal, on terms consistent with the lesion rather than naming it.
- MelphalanAlkylator1.75 (1.52–2.02) · n=186 Reporting signal.
- OsimertinibEGFR TKI1.71 (1.49–1.97) · n=198 Reporting signal.
- ChlorambucilAlkylating agent (nitrogen mustard)1.39 (0.92–2.09) · n=23 No reporting signal.
- LazertinibEGFR TKI (3rd-gen)1.10 (0.41–2.93) · n=4 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no SIADH reports, or too few (count in brackets): Vinflunine
No ratio — under 50 FAERS reports in total: Sunvozertinib
All 24 agents documented with SIADH in the atlas are shown whether or not FAERS flags them, plus the 108 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). 128 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
Management approach
Full framework →Manage the hyponatremia (fluid restriction, careful correction); avoid over-hydration around dosing.
Drug-level levers
- Avoid the large hypotonic fluid loads historically given with cyclophosphamide.
- Adjust dose timing and hydration strategy.
Pharmacologic toolkit
- Fluid restriction — First line for euvolemic hyponatremia.
- Careful sodium correction — Correct slowly to avoid osmotic demyelination syndrome.
When to biopsy
Not indicated — a water-handling disorder, not structural injury.
Monitoring
- · Serum sodium around dosing
- · Fluid balance
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
Offending agents
Signature offenders
12Agents for which siadh / hyponatremia is the defining renal lesion.
Also associated
12Agents that cause siadh / hyponatremia as a secondary pattern alongside a different signature lesion.